Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | DNM2 | P50570 | 7/20 | 0.42 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1785420 | 0.82 | ABL1 (0.51) | ABL1DNM2KCNH3S1PR2LMNA | |
| SCHEMBL1784168 | 0.80 | ABL1 (0.44) | ABL1ACHEDNM2KCNH3S1PR2 | |
| SCHEMBL1782973 | 0.79 | SMN1; SMN2 (0.54) | LMNASMN1; SMN2 | |
| SCHEMBL8216585 | 0.77 | ABL1 (0.53) | ABL1ACHEDNM2KCNH3S1PR2 | |
| SCHEMBL8212647 | 0.77 | ABL1 (0.53) | ABL1ACHEDNM2KCNH3S1PR2 | |
| SCHEMBL8214084 | 0.77 | ABL1 (0.53) | ABL1ACHEDNM2KCNH3S1PR2 | |
| SCHEMBL1783878 | 0.77 | ABL1 (0.47) | ABL1ACHEDNM2KCNH3S1PR2 | |
| SCHEMBL18386498 | 0.75 | KCNH3 (0.48) | ABL1DNM2KCNH3S1PR2LMNA | |
| Decane SCHEMBL11419386 | 0.75 | KDM4E (0.50) | SMN1; SMN2 | |
| Hexadecane SCHEMBL11412808 | 0.75 | KDM4E (0.50) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445511-B2 | Quinoline or quinoxaline derivatives for treating neurodegenerative diseases | Centre National de la Recherche Scientifique (SNRS) (FR) | 2013-05-21 | — | — | US | disclosed |
| US-20110118270-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118270-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HCRTR2, HCRTR1, CHRNA2 | ABL1 3272/4885ACHE 848/4885DNM2 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.